Clinical data
ATC code
  • None
  • N-[7-Isopropyl-6-(2-methylpyrazol-3-yl)-2,4-dioxo-1H-quinazolin-3-yl]methanesulfonamide
CAS Number
PubChem CID
CompTox Dashboard (EPA)
Chemical and physical data
Molar mass377.42 g·mol−1
3D model (JSmol)
  • CC(C)c1cc2c(cc1c3ccnn3C)c(=O)n(c(=O)[nH]2)NS(=O)(=O)C
  • InChI=1S/C16H19N5O4S/c1-9(2)10-8-13-12(7-11(10)14-5-6-17-20(14)3)15(22)21(16(23)18-13)19-26(4,24)25/h5-9,19H,1-4H3,(H,18,23)

Selurampanel (INN, code name BGG492) is a drug closely related to the quinoxalinedione series which acts as a competitive antagonist of the AMPA and kainate receptors and, as of 2015, is being investigated in clinical trials by Novartis for the treatment of epilepsy.[1][2][3] It has also been studied in the acute treatment of migraine, and was found to produce some pain relief, but with a relatively high rate of side effects.[4]


  1. ^ Faught, Edward (2014). "BGG492 (selurampanel), an AMPA/kainate receptor antagonist drug for epilepsy". Expert Opinion on Investigational Drugs. 23 (1): 107–113. doi:10.1517/13543784.2014.848854. ISSN 1354-3784. PMID 24147649. S2CID 40105670.
  2. ^ Belcastro, Vincenzo; Verrotti, Alberto (2015). "Novel Molecular Targets for Drug-Treatment of Epilepsy". Epilepsy Towards the Next Decade. pp. 183–199. doi:10.1007/978-3-319-12283-0_10. ISBN 978-3-319-12282-3.
  3. ^ Hanada, Takahisa (2014). "The AMPA receptor as a therapeutic target in epilepsy: preclinical and clinical evidence". Journal of Receptor, Ligand and Channel Research: 39. doi:10.2147/JRLCR.S51475. ISSN 1178-699X.
  4. ^ Gomez-Mancilla B, Brand R, Jürgens TP, et al. (February 2014). "Randomized, multicenter trial to assess the efficacy, safety and tolerability of a single dose of a novel AMPA receptor antagonist BGG492 for the treatment of acute migraine attacks" (PDF). Cephalalgia. 34 (2): 103–13. doi:10.1177/0333102413499648. PMID 23963355. S2CID 206520491.